More M&A For GSK

UK pharmaceutical firm GlaxoSmithKline (GSK) has reiterated its 'diversify to de-risk' strategy during October 2008 with three medium size acquisitions, all focused away from traditional blockbuster pharmaceuticals. BMI sees GSK's bold attitude towards coping with growing sector-specific pressures - such as patent expiries, faltering product pipelines and added requirements to demonstrate true product value - as well as the global economic slowdown, as a sign of strength from the world's second largest drugmaker. Furthermore, with over GBP5.1bn (US$7.9bn) of cash or cash equivalents on the balance sheet at the end of the third quarter of 2008 and CEO Andrew Witty

To read the full article, please choose one of the following options: